Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation

International Journal of Hematology

Volumn 83, Issue 5, 2006, Pages 454-458

  Osugi, Yuko ^a   Yamada, Hiroshi ^a   Hosoi, Gaku ^a   Noma, Haruyoshi ^a   Ikemiya, Misako ^a   Ishii, Takefumi ^a   Sako, Masahiro ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Allogeneic stem cell transplantation; Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Candesartan; Chronic GVHD; Membranous nephropathy; Nephrotic syndrome

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; THIOTEPA; TSUKUBAENOLIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MALE; NEPHROTIC SYNDROME; PROTEINURIA; REMISSION; WHOLE BODY RADIATION;

ADOLESCENT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; NEPHROTIC SYNDROME; PROTEINURIA; STEM CELL TRANSPLANTATION; TETRAZOLES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33751040624     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05183     Document Type: Article

References (15)

1. Akar H, Keven K, Celebi H, et al. Nephrotic syndrome after allogeneic peripheral blood stem cell transplantation. J Nephrol. 2002;15:79-82.
2. Lin J, Markowitz GS, Nicolaides M, et al. Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Am J Nephrol. 2001;21:351-356.
3. Imai H, Oyama Y, Miura AB, Endoh M, Sakai H. Hematopoietic cell transplantation-related nephropathy in Japan. Am J Kidney Dis. 2000;36:474-480.
4. Nergizoglu G, Keven K, Ates K, et al. Chronic graft-versus-host disease complicated by membranous glomerulonephritis. Nephrol Dial Transplant. 1999;14:2461-2463.
5. Sato N, Kishi K, Yagisawa K, et al. Nephrotic syndrome in a bone marrow transplant recipient with chronic graft-versus-host disease. Bone Marrow Transplant. 1995;16:303-305.
6. Tsutsumi C, Miyazaki Y, Fukushima T, et al. Membranous nephropathy after allogeneic stem cell transplantation: report of 2 cases. Int J Hematol. 2004;79:193-197.
7. Miyazaki Y, Mori Y, Kishimoto N, et al. Membranous nephropathy associated with donor lymphocyte infusion following allogeneic bone marrow transplantation. Int J Hematol. 2003;78:262-265.
8. Clark AG, Barratt TM. Steroid-responsive nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE, eds. Pediatric Nephrology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:731-747.
9. Niaudet P. Steroid-resistant idiopathic nephrotic syndrome. In: Barratt TM, Avner ED, Harmon WE, eds. Pediatric Nephrology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:749-764.
10. Schweda F, Liebl R, Riegger GA, Kramer BK. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant. 1997;12:2433-2435.
11. Kurokawa K. Effects of candesartan on the proteinuria of chronic glomerulonephritis. J Hum Hypertens. 1999;13(suppl 1):S57-S60.
12. Hilgers KF, Dotsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol. 2004;19:956-961.
13. Romagnani P, Lazzeri E, Mazzinghi B, et al. Nephrotic syndrome and renal failure after allogeneic stem cell transplantation: novel molecular diagnostic tools for a challenging differential diagnosis. Am J Kidney Dis. 2005;46:550-556.
14. Makker SP. Membranous glomerulonephropathy. In: Barratt TM, Avner ED, Harmon WE, eds. Pediatric Nephrology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:719-730.
15. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003;26:2268-2274.